{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:00:39Z","timestamp":1794852039689,"version":"4.9.1"},"reference-count":33,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Economic Affairs, ROC","award":["109-EC-17-A-22-1587"],"award-info":[{"award-number":["109-EC-17-A-22-1587"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Albumin-binding agents enhance tumor uptake of radiopharmaceuticals targeting prostate-specific membrane antigens (PSMAs) in radiotherapy. We synthesized PSMA-NARI-56, a molecule with both PSMA targeting activity and albumin-binding moiety, labeled with 177Lu as the therapeutic agent. The aim of this study was to determine the specific binding of 177Lu-PSMA-NARI-56 towards PSMA, assess its biodistribution, and evaluate therapeutic effectiveness by tumor-bearing mice. The effect of 177Lu-PSMA-NARI-56 viability of PSMA-positive cell (LNCaP) was evaluated. Biodistribution and endoradiotherapy studies were utilized to determine the distribution, targeting, and anti-tumor efficacy by tumor-bearing mice identified by 111In-PSMA-NARI-56. 177Lu-PSMA-NARI-56 exhibited a significant impact on the viability of the LNCaP cell. Biodistribution results revealed the maximum tumor uptake of 177Lu-PSMA-NARI-56 occurring within 24 h, reaching 40.56 \u00b1 10.01%ID\/g. In radionuclide therapy, at 58 days post-injection (p.i.), 177Lu-PSMA-NARI-56 demonstrated superior tumor inhibition (98%) compared to 177Lu-PSMA-617 (58%), and the mouse survival rate after 90 days of radiotherapy (90%) was also higher than that of 177Lu-PSMA-617 (30%) in LNCaP tumor-bearing mice. In the PSMA-positive animal model, 177Lu-PSMA-NARI-56 shows higher potential radiotheranostic and prolonged accumulation (identify by 111In-PSMA-NARI-56\/nanoSPECT\/CT image), offering the potential for improved treatment effectiveness and increased survival rates when compared to 177Lu-PSMA-617.<\/jats:p>","DOI":"10.3390\/ijms26157580","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:45:11Z","timestamp":1754466311000},"page":"7580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1546-6877","authenticated-orcid":false,"given":"Ming-Wei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ruei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lin","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2734-2096","authenticated-orcid":false,"given":"Shih-Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 32546, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-3603","authenticated-orcid":false,"given":"Kang-Wei","family":"Chang","sequence":"additional","affiliation":[{"name":"Taipei Neuroscience Institute & Laboratory Animal Center, Taipei Medical University, Taipei 110301, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","article-title":"Pain predicts overall survival in men with metastatic castration-refractory prostate cancer","volume":"26","author":"Halabi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Elgqvist, J., Frost, S., Pouget, J.P., and Albertsson, P. (2014). The potential and hurdles of targeted alpha therapy\u2014Clinical trials and beyond. Front. Oncol., 3.","DOI":"10.3389\/fonc.2013.00324"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.1988.6.11.1746","article-title":"The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy","volume":"6","author":"Richardson","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique","volume":"50","author":"Zhang","year":"2007","journal-title":"Histopathology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.21065","article-title":"Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid","volume":"70","author":"Yao","year":"2010","journal-title":"Prostate"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12105-021-01376-8","article-title":"Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors","volume":"16","author":"Nishida","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"ref_13","first-page":"e29369","article-title":"A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer","volume":"14","author":"Alam","year":"2022","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","article-title":"Current status of theranostics in prostate cancer","volume":"45","author":"Virgolini","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","article-title":"Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.7150\/thno.18719","article-title":"(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice","volume":"7","author":"Choy","year":"2017","journal-title":"Theranostics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","article-title":"Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer","volume":"58","author":"Kelly","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing Treatment Efficacy of (177)Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lo, W.L., Lo, S.W., Chen, S.J., Chen, M.W., Huang, Y.R., Chen, L.C., Chang, C.H., and Li, M.H. (2021). Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115459"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1021\/acs.bioconjchem.8b00292","article-title":"Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10456-012-9328-3","article-title":"Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models","volume":"16","author":"Eichten","year":"2013","journal-title":"Angiogenesis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"(177)Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"Umbricht","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","first-page":"2217","article-title":"Biodistribution, pharmacokinetics and microSPECT\/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model","volume":"27","author":"Chang","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s003350010240","article-title":"Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen\/NAALADase\/folate hydrolase","volume":"12","author":"Bacich","year":"2001","journal-title":"Mamm. Genome"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2967\/jnumed.117.194209","article-title":"Repeated (177)Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq","volume":"59","author":"Rathke","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.114.147181","article-title":"PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","article-title":"Establishing (177)Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00259-017-3791-4","article-title":"Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: Preliminary results","volume":"44","author":"Matteucci","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:23:54Z","timestamp":1760034234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":33,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26157580"],"URL":"https:\/\/doi.org\/10.3390\/ijms26157580","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}